# Human Placenta Hydrolysate Protects Against Acetaminophen-Induced Liver Injury in Mice

**Authors:** Inyoung Hwang, Chi-Gu Kang, So-Jung Lim, Hyun-Jin Kim, Ryun Kang, So-Hyun Jeon, Sang-Hoon Lee, Jae-Won Kim, Ju-Seop Kang

PMC · DOI: 10.3390/biomedicines13051219 · Biomedicines · 2025-05-18

## TL;DR

This study shows that human placenta hydrolysate protects mice from liver damage caused by acetaminophen overdose.

## Contribution

The study demonstrates the hepatoprotective effects of human placenta hydrolysate against acetaminophen-induced liver injury in mice.

## Key findings

- HPH pretreatment reduced liver necrosis and congestion and lowered serum liver enzyme levels.
- HPH modulated detoxification enzymes and exhibited antioxidant and anti-inflammatory effects.
- HPH improved hepatocyte viability in a concentration-dependent manner.

## Abstract

Background/Objectives: Acetaminophen (APAP) is a widely used analgesic and antipyretic, but overdose can lead to APAP-induced liver injury (AILI), a major cause of acute liver failure. While N-acetylcysteine (NAC) is the current standard of care, its efficacy is significantly reduced when administered after the peak time of liver injury, highlighting the need for alternative therapeutic strategies. Human placenta hydrolysate (HPH) has shown potential as a therapeutic agent for various liver diseases due to its rich content of bioactive compounds. This study aimed to investigate the hepatoprotective effects of HPH in a mouse model of AILI. Methods: HPH was administered to mice for three days prior to APAP treatment. The effects of HPH on liver morphology, necrosis, liver enzymes, phase I/II detoxification enzymes, oxidative stress markers, and inflammatory cytokines were evaluated. Results: HPH pretreatment attenuated APAP-induced liver necrosis and congestion, reduced serum levels of liver enzymes. In addition, HPH showed a concentration-dependent attenuation of APAP-induced decrease in human hepatocyte viability. HPH modulated phase I/II enzyme expression by downregulating CYP2E1 and upregulating SULT1A1, UGT1A6, GSTP1, and TPMT. HPH also exhibited antioxidant effects by increasing SOD and GPx activities, reducing MDA levels, and restoring the GSH/GSSG ratio. Furthermore, HPH attenuated the APAP-induced increase in the inflammatory cytokines TNF-α and IL-6. These findings suggest that HPH protects against AILI through multiple mechanisms, including the modulation of phase I/II detoxification, activation of antioxidants, and inhibition of inflammation. Conclusions: HPH could be a potential therapeutic option for APAP overdose and related liver injuries.

## Linked entities

- **Proteins:** CYP2E1 (cytochrome P450 family 2 subfamily E member 1), SULT1A1 (sulfotransferase family 1A member 1), UGT1A6 (UDP glucuronosyltransferase family 1 member A6), GSTP1 (glutathione S-transferase pi 1), TPMT (thiopurine S-methyltransferase), SOD1 (superoxide dismutase 1), GPX (probable phospholipid hydroperoxide glutathione peroxidase), so (sine oculis), TNF (tumor necrosis factor), IL6 (interleukin 6)
- **Chemicals:** Acetaminophen (PubChem CID 1983), N-acetylcysteine (PubChem CID 12035)
- **Diseases:** Acute liver failure (MONDO:0019542)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CYP2E1 (cytochrome P450 family 2 subfamily E member 1) [NCBI Gene 1571] {aka CPE1, CYP2E, P450-J, P450C2E}, UGT1A6 (UDP glucuronosyltransferase family 1 member A6) [NCBI Gene 54578] {aka GNT1, HLUGP, HLUGP1, UDPGT 1-6, UGT-1F, UGT1-06}, SULT1A1 (sulfotransferase family 1A member 1) [NCBI Gene 6817] {aka HAST1/HAST2, P-PST, P-PST 1, PST, ST1A1, ST1A3}, TPMT (thiopurine S-methyltransferase) [NCBI Gene 7172] {aka TPMTD}, GSTP1 (glutathione S-transferase pi 1) [NCBI Gene 2950] {aka DFN7, FAEES3, GST3, GSTP, GSTP1-1, HEL-S-22}
- **Diseases:** liver diseases (MESH:D008107), Liver Injury (MESH:D017093), necrosis (MESH:D009336), inflammation (MESH:D007249), acute liver failure (MESH:D017114), overdose (MESH:D062787)
- **Chemicals:** GSH (MESH:D005978), GSSG (MESH:D019803), AILI (-), N-acetylcysteine (MESH:D000111), MDA (MESH:D015104), APAP (MESH:D000082)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12109462/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12109462/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12109462/full.md

---
Source: https://tomesphere.com/paper/PMC12109462